Hypoalbuminemia, body mass index, and weight loss as predictors of outcomes in head and neck cancer.

Authors

null

Kim Robyn Kennedy

Fiona Stanley Hospital, Murdoch, Western Australia, Australia

Kim Robyn Kennedy , Daren Joseph Gibson , Stephanie Flukes , Chandra Sai Diwakarla , Lisa Jane Spalding , Andrew David Redfern

Organizations

Fiona Stanley Hospital, Murdoch, Western Australia, Australia, University of Western Australia, Murdoch, Western Australia, Australia

Research Funding

Other Government Agency
Western Australian Cancer and Palliative Care Network Fellowship Grant

Background: Malnutrition is a major complication of head and neck cancer and has pertinent implications on survival. Methods: We performed a retrospective analysis of 320 patients with head and neck cancer from a tertiary hospital in Western Australia from 2013 - 2021. Weight and albumin were collected from different timepoints in the patient’s journey, including at diagnosis and end of treatment. Treatments received, recurrences and survival data were also collected. Initial univariate analyses were performed using Chi squares. Results: Median follow-up was 2.6 years (range 16 days to 9 years). 44% of patients underwent curative intent radiotherapy or chemoradiotherapy, 38% had surgery (+/- adjuvant therapies), 9% had palliative treatments, and 9% had best supportive care. At diagnosis, 12% of patients were hypoalbuminemic, 75% had normal albumin, and albumin was unknown in 13%. Hypoalbuminemia at diagnosis strongly correlated with lower survival compared with patients with normal albumin with 1 year OS (1YS) 35% vs 82% (p < 0.00001). Patients with normal albumin at diagnosis had higher disease-free survival compared to hypoalbuminemic patients (56% vs 32%, p = 0.04). By the end of treatment, 22% of patients were hypoalbuminemic, 48% had normal albumin, and 30% were unknown. Hypoalbuminemia at end of treatment was also prognostic, with 1YS 72% vs 89% and 2YS 52% vs 72% (p = 0.002) when compared to patients with normal albumin. Of patients who were treated with curative intent, there was no significant difference in the rate of relapse (38% vs 35%, p = 0.67). By Body Mass Index (BMI) at diagnosis, 5% of patients were severely underweight (BMI < 16.5), 7% underweight (BMI 16.5-18.4), 34% healthy (BMI 18.5-24.9), 31% overweight (BMI 25.0-29.9), and 22.5% obese (BMI ≥30). BMI at diagnosis was highly prognostic with 1YS 37% in severely underweight patients, 67% underweight, 75% healthy, 91% overweight, and 94% in obese individuals (p < 0.00001). By end of treatment, 7% were severely underweight, 9% were underweight, 42% were healthy, 28% were overweight, and 14% were obese. Low BMI at end of treatment was also associated with inferior outcomes with 1YS 53% in severely underweight individuals, 76% underweight, 83% healthy, 97% overweight, and 95% in obese patients (p < 0.00001). Median weight loss from diagnosis to end of treatment was 6kg (range from 34kg loss to 15kg gain), and median % body weight change was -7.5% (range from -28% to +26%). Percentage body weight loss of > 20% was associated with worse survival with 65% mortality during the study period compared with 35% in patients who lost ≤20% body weight. 1YS was 71% in patients who lost > 20% body weight compared to 86%, although this did not reach statistical significance (p = 0.097). Conclusions: Hypoalbuminemia and low BMI at diagnosis and end of treatment, in addition to % body weight loss of > 20% were all associated with worse survival in head and neck cancer patients.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e18027)

DOI

10.1200/JCO.2023.41.16_suppl.e18027

Abstract #

e18027

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Genitourinary Cancers Symposium

Association of body-mass index (BMI) with age, PSA, and survival in metastatic prostate cancer.

First Author: Martin W. Schoen

First Author: Sakditad Saowapa

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Preoperative weight loss program for hepatocellular carcinoma patients with high body mass index in hepatectomy.

First Author: Yu Saito